Clinical Trial Detail

NCT ID NCT02630186
Title A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Clovis Oncology, Inc.
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab + Rociletinib

Age Groups: adult

No variant requirements are available.